Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Preferred Stock Liabilities (2017 - 2020)

Outlook Therapeutics (OTLK) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $6.5 million as the latest value for Q1 2020.

  • Quarterly Preferred Stock Liabilities rose 28.34% to $6.5 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Mar 2020, up 28.34% year-over-year, with the annual reading at $5.4 million for FY2019, 13.2% up from the prior year.
  • Preferred Stock Liabilities for Q1 2020 was $6.5 million at Outlook Therapeutics, down from $8.3 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $18.3 million in Q1 2018, with the low at $2.9 million in Q3 2017.
  • Average Preferred Stock Liabilities over 4 years is $7.5 million, with a median of $5.2 million recorded in 2019.
  • Peak annual rise in Preferred Stock Liabilities hit 69.91% in 2019, while the deepest fall reached 72.46% in 2019.
  • Over 4 years, Preferred Stock Liabilities stood at $17.2 million in 2017, then crashed by 71.58% to $4.9 million in 2018, then surged by 69.91% to $8.3 million in 2019, then dropped by 22.08% to $6.5 million in 2020.
  • According to Business Quant data, Preferred Stock Liabilities over the past three periods came in at $6.5 million, $8.3 million, and $5.4 million for Q1 2020, Q4 2019, and Q3 2019 respectively.